ribavirin has been researched along with Cirrhosis in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (46.94) | 29.6817 |
| 2010's | 23 (46.94) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Abdel-Rahman, YO; Abdel-Razik, W; Dabbous, HM; Elakel, W; Elmakhzangy, H; Elshafaey, A; Esmat, G; Ismail, SA; Omar, H; Saeed, R; Salama, R; Waked, I; Ziada, DH | 1 |
| Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A | 1 |
| Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A | 1 |
| El-Raziky, M; Elsharkawy, A; Fouad, A; Khairy, M; Salama, A; Tantawy, O | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Aziz, S; Mirza, T; Sohail, S | 1 |
| Rakela, J; Unzueta, A | 1 |
| Chiba, T; Fujimoto, Y; Haga, H; Ito, T; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
| El Zanaty, T; Mohamed Seif, S; Mostafa, A; Omran, MH; Saad, A; Youssef, SS | 1 |
| Aghemo, A; Castaldi, D; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Grassi, E; Rumi, MG; Soffredini, R | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Aguilar, H; Asatryan, A; Gane, E; Hassanein, T; Kort, J; Kwo, PY; Lalezari, J; Lin, CW; Liu, R; Maliakkal, B; Mensa, FJ; Ng, TI; Poordad, F; Wang, S; Wyles, DL | 1 |
| El-Karaksy, HM; El-Mougy, FA; Mandour, IA; Mogahed, EA; Rady, NH; Sharaf, SA | 1 |
| Antosik, D; Barcińska, D; Bereszyńska, I; Januszkiewicz-Lewandowska, D; Kałużna, E; Mozer-Lisewska, I; Nowak, J; Rembowska, J; Strauss, E; Świątek-Kościelna, B; Wysocki, J | 1 |
| Boumis, E; Capone, A; Drapeau, CM; Noto, P; Petrosillo, N; Remotti, D | 1 |
| Blanc, F; Clot, J; Corbeau, P; Perney, P; Portalès, P; Psomas, C; Rigole, H; Turriere, C | 1 |
| Zeuzem, S | 1 |
| Guturu, P; Jaganmohan, S; Kuo, YF; Mummadi, R; Singal, AK; Singh, A; Sood, GK | 1 |
| Bortolotti, F; Brugiolo, A; Carli, M; Cesaro, S; Guido, M; Petris, MG | 1 |
| Alcaide, N; Aller, R; Almansa, R; Bermejo-Martin, JF; Caro-Paton, A; de la Fuente, C; de Lejarazu, RO; Gonzalez, JM; Jimenez-Sousa, MA; Largo, P; Resino, S; Ruiz, L; Sanchez-Antolín, G | 1 |
| Borque, MJ; Chaparro, M; González-Moreno, L; Mendoza, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Bzowej, N; Charlton, MR; Everson, GT; Nelson, DR; Prabhakar, A; Teng, LL; Terrault, NA | 1 |
| Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM | 1 |
| Dróżdż, W; Dybowska, D; Halota, W; Kozielewicz, D | 1 |
| Bai, F; Bellistrì, GM; Borghi, F; Carosi, G; Gatti, F; Marchetti, G; Monforte, Ad; Nasta, P; Puoti, M; Tincati, C | 1 |
| Asselah, T | 1 |
| Bronowicki, JP | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Hu, R; Ibrahim, AB; Kunder, G; Lassman, C; Saab, S; Yersiz, H | 1 |
| Imawari, M; Nakamura, I; Ochiai, K | 1 |
| Iwasaki, Y; Shiraha, H; Shiratori, Y | 1 |
| Yamada, G | 1 |
| Lai, CL; Yuen, MF | 1 |
| Simon, K; Szymczak, A | 1 |
| Herrmann, E; Mihm, U; Sarrazin, C; Zeuzem, S | 1 |
| Capelli, P; Corrocher, R; De Franceschi, L; Fattovich, G; Felder, M; Guido, M; Lanza, C; Leandro, G; Olivari, N; Pasino, M; Rugge, M | 1 |
| Adenwalla, M; Cheong-Lee, C; Ma, PE; Yoshida, EM; Zandieh, I | 1 |
| Bolkhir, A; Brunt, EM; Hayashi, PH; Solomon, HS | 1 |
| Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP | 1 |
| Armstrong, EP; Malone, DC; Skrepnek, GH; Yeh, WS | 1 |
| Berberat, PO; Encke, J; Gotthardt, D; Mehrabi, A; Merle, U; Riediger, C; Sauer, P; Stremmel, W; Weiss, KH | 1 |
| Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS | 1 |
| Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B | 1 |
| Berntorp, E; Lethagen, S; Lindgren, S; Verbaan, H; Widell, A | 1 |
| Alaimo, G; Almasio, PL; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Peralta, S; Rodolico, V; Vaccaro, A | 1 |
| Ashur, Y; Granot, E; Shouval, D | 1 |
11 review(s) available for ribavirin and Cirrhosis
| Article | Year |
|---|---|
Hepatitis E infection in liver transplant recipients.
Topics: Animals; Chronic Disease; Disease Progression; Feces; Fibrosis; Food Microbiology; Hepatitis E; Humans; Immunosuppression Therapy; Interferons; Liver; Liver Failure; Liver Transplantation; Ribavirin; RNA, Viral | 2014 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Assessment | 2010 |
Interferon stimulated genes and hepatitis C virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2012 |
[Treatment of hepatitis C virus-related cirrhosis].
Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Time Factors | 2002 |
[Clinical management of asymptomatic HCV carriers].
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Carrier State; Contraindications; Drug Therapy, Combination; Fibrosis; Hepatitis C; Humans; Interferons; Liver; Practice Guidelines as Topic; Ribavirin | 2004 |
[Evaluating the efficacy of interferon therapy on hepatitis C patients].
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Neoplasms; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid | 2004 |
[Molecular virology and treatment of patients with chronic hepatitis C].
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Neoplasms; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
Review article: predicting response in hepatitis C virus therapy.
Topics: Antiviral Agents; Fibrosis; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Prognosis; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
Topics: Antiviral Agents; Fibrosis; Hepatitis B, Chronic; Hepatitis, Chronic; Humans; Immunoglobulins; Interferons; Liver Transplantation; Polyethylene Glycols; Recurrence; Ribavirin; Treatment Outcome | 2007 |
8 trial(s) available for ribavirin and Cirrhosis
| Article | Year |
|---|---|
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides | 2020 |
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response | 2016 |
CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Fibrosis; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Receptors, CCR5; Receptors, CXCR3; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Biopsy; End Stage Liver Disease; Female; Fibrosis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2011 |
Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C; Hong Kong; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Viremia | 2006 |
High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Fibrosis; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Failure; Vascular Cell Adhesion Molecule-1 | 2001 |
30 other study(ies) available for ribavirin and Cirrhosis
| Article | Year |
|---|---|
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis.
Topics: Adult; Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin | 2023 |
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.
Topics: Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Sofosbuvir | 2018 |
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.
Topics: Adult; Aged; Biopsy; Cross-Sectional Studies; Fatty Liver; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Failure; Ultrasonography; Young Adult | 2013 |
Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Interferons; Liver Failure; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients.
Topics: Adult; Egypt; Female; Fibrosis; Genetic Association Studies; Genotype; Hepatitis C; Humans; Interferons; Interleukin-12 Subunit p40; Liver; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Ribavirin; Sex Factors; Treatment Outcome | 2013 |
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Early Diagnosis; Female; Fibrosis; Genetic Variation; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin | 2014 |
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
Topics: Adolescent; Alleles; Antiviral Agents; Child; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Liver; Male; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Treatment Outcome; Viral Load | 2016 |
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-10; Liver; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2017 |
Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy.
Topics: Antiviral Agents; Bone Marrow; Bone Marrow Diseases; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancytopenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Forewarned is forearmed.
Topics: Antiviral Agents; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy.
Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Neoplasms; Ribavirin; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Down-Regulation; Drug Therapy, Combination; Fibrosis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer; Viral Load | 2010 |
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leukopenia; Male; Middle Aged; Poland; Polymerase Chain Reaction; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2011 |
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Topics: Adult; Bacteria; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Demography; Female; Fibrosis; Hepatitis C, Chronic; HIV Infections; HLA-DR Antigens; Humans; Interferon-alpha; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Solubility; Treatment Outcome | 2012 |
Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Erythropoietin; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2003 |
Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2005 |
Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloproteases; Middle Aged; NF-kappa B; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2006 |
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepatitis C, Chronic; Humans; Indians, North American; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin | 2006 |
Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viremia | 2007 |
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention | 2007 |
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Topics: Age Factors; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrosis; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States; United States Department of Veterans Affairs | 2007 |
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin | 2007 |
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine | 2007 |
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Genotype; Hemophilia A; Hepatitis C; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Ultrasonography; von Willebrand Diseases | 2001 |